SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes

Not Applicable

Completed

• Conditions: Covid19
• Interventions: Diagnostic Test: Anti-SARS-CoV2 Serology

• Registration Number: NCT04816084
• Lead Sponsor: Université de Reims Champagne-Ardenne

Brief Summary

This study was designed to determine, in a screening situation within the framework of university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the staff of the University of Reims Champagne-Ardenne. The serological tests chosen will allow systematic detection of anti-SARS-CoV-2 IgM and anti-SARS-Cov-2 IgG to assess the moment of potential contamination prior to resumption of occupational activity.

Detailed Description

Objective:

This study was designed to determine, in a screening situation within the framework of university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the staff of the University of Reims Champagne-Ardenne. The serological tests chosen will allow systematic detection of anti-SARS-CoV-2 IgM and anti-SARS-Cov-2 IgG to assess the moment of potential contamination prior to resumption of occupational activity.

Type of study:

This is a prevalence study, a single-center cross-sectional study published on the human person.

Population:

Inclusion criteria: On a voluntary basis, the staff of the University of Reims Champagne Ardenne will be offered a serological blood test (1 dry tube of 7ml). The use of the collected data for research purposes will be explained to each requester, with signature of an informed consent. Only people over 18 will be included.

Non-inclusion criteria: Staff of the University of Reims Champagne Ardenne who have not requested to be tested. Duration of participation of subjects: 1/2 day time

Judgment criterion (s):

Main endpoint (in connection with the main objective): Prevalence of positive SARS-CoV-2 serology at the University of Reims Champagne-Ardenne.

Clinical investigation plan:

* Phase 1: Communication strategy An email will be sent to all the staff of the University of Reims Champagne Ardenne to offer them anti-SARS-Cov-2 serological tests, as part of a health research protocol. Before sampling, a questionnaire will be completed by the applicant.

* Phase 2: Analysis of the samples

* Phase 3: Transmission of results to Pr Frédéric Deschamps, head of SUMMPS at the University of Reims Champagne Ardenne

Study Timeline

• Study Start: 2020-11-05
• Primary Completion: 2020-12-01
• Status Verified: 2021-03
• Study Completion: 2021-03-15
• Study First Submitted: 2021-03-19
• Study First Submitted QC: 2021-03-24
• Last Update Submitted: 2021-03-24
• Study First Posted: 2021-03-25
• Last Update Posted: 2021-03-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 389

Inclusion Criteria

• Major volunteers from the Staff of the University of Reims Champagne-Ardenne (>18 years old)

Exclusion Criteria (Non Inclusion):

• persons who do not desire to participate

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Population	Anti-SARS-CoV2 Serology	Voluntary people over 18 from the staff of the University of Reims Champagne Ardenne

Primary Outcome Measures

Name	Time	Method
Prevalence of IgG and IgM anti-SARS CoV2 antibodies	Inclusion time was ½ day, time for blood sampling	Anti-SARS-Cov2 seroprevalence measured in blood sample collected at Day 0.

Trial Locations

Locations (1)

Université de Reims Champagne-Ardenne; 🇫🇷 Reims, France